



final

GYNECOLOGIC CANCER INTERGROUP (GCIG)
MEMBERSHIP -- GENERAL ASSEMBLY
 FRIDAY, NOV.7, 2014, 2:45PM – 4:15PM
 BRIDGE 5 ROOM, CROWNE PLAZA HOTEL, MELBOURNE

CHAIR: BILL SMALL

PAST CHAIR: ERIC PUJADE-LAURAINÉ

AGENDA

Sign-in of Attendance Form is critical

<u>Welcome and Introductions</u> (COI declarations)	Small
<u>Secretariat Report</u>	
<u>Operations</u>	Bacon
<ul style="list-style-type: none"> - G.A. minutes May 2014. Motion: _____ - Finances (outstanding dues) - Attendance and representation 	
<u>Webmaster</u>	Powers
<ul style="list-style-type: none"> - Website update - Evaluation Forms for Attendance certificates - Bibliography/Publications/manuscripts/presentations– updates 	
<u>Membership Committee Report:</u>	
Update (& Mentorship) (& criteria revisions)	Stuart
GCIG Citations report	Stuart
<u>Executive – Board of Directors Report:</u>	Small
Strategic Planning plan (incl. mission statement, funding, membership, mentoring, megadatabase potential, support, education, QA, Principles Independence, future directions, etc)	
<ul style="list-style-type: none"> - Executive Officers/Committee - Incorporation; Governance & Statutes; Grants. - Overall Scheduling; Satellites. - co-Chair SBwg transfer 	
<u>Member Groups:</u> Update	
<p style="margin-left: 40px;"><u>Full members:</u> ACRIN (absent), AGO-Au, AGO-De, ANZGOG, COGI, DGOG, EORTC-GCG, GEICO, GICOM, GINECO, GOG, GOTIC, ICORG (absent), JGOG, KGOG, MaNGO, MITO, MRC/NCRI, NCIC CTG, NSGO, PMHC, RTOG, SGCTG, SGOG.</p> <p style="margin-left: 40px;"><u>Governmental/Reg. Authorities:</u> Full Member: NCI US</p>	

Provisional Members: NOGGO, BGOG, G-GOC
Observers/Interested:

Industry Partners: AMGEN, ASTRA-ZENECA, BOEHRINGER-INGELHEIM, ELI LILLY, GSK, PHARMAMAR, ROCHE, TAIHO, ZERIA, ELEKTA-NUCLETRON, TESARO.

Liaisons: ISSTD, WSN, ENGOT, BIG.

Disease Sites:

Endometrial Cancer (+ GTD):

- Committee report Lorusso/Greggi

Cervix Cancer (+ vulvar, vagina):

- Cx Ca Brainstorming report Sagae/Monk
- Cervix Cancer Research Network (CCRN) report Gaffney/Ryu

Ovarian Cancer:

- Committee report Harter/Gonzalez
- 5th OCCC status update (Nov. 2015) Okamoto

Harmonization: Committee Reports:

- Operations Bryce/Stonebraker
- Statistics Nam/Reuss

Translational Research: Committee Report:

Scott/Gourley

Working Groups:

- Rare Tumours - report and Nov. 2013 brainstorming outcome Ray-Coquard/Ledermann
- Symptom Benefit report (ov., en., cx., elderly, survivorship, QoL, etc) Joly/Hilpert
- Phase II report Oza/Kohn

FIGO (& WHO) Liaison Report:

Quinn

OTHER BUSINESS:

Adjourn

Next Meetings

- May 27-28, 2015, Chicago (pre-ASCO) (May 26, 4pm, Exec-BoD Strategic Planning)
- November 10 & 11, 2015, Tokyo (with 5th OCCC Nov. 7-9,2015)(ASGO Nov. 12-14, 2015 Seoul, Korea)
- June 1-2, 2016 Chicago (pre- ASCO)
- November 2016 ?????
- May 31 – June 1, 2017 Chicago (pre-ASCO)
- November 2017 ?????
- May 30 – 31, 2018 Chicago (pre-ASCO)
- November 2018 ???
- May 29 – 30, 2019 Chicago (pre-ASCO)

- November 2019 ???
- May 27 – 28, 2020 Chicago (pre-ASCO)